SL Therapeutics, Inc.

A258540

KR7258540004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
730 ^KRW	0.00%		-9.77%	+23.94%

2022	StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	CI
2022	StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	CI

StemLab Inc. announced that it has received KRW 1.5 billion in funding

March 29, 2019

On March 29, 2019, StemLab Inc. (XKON:A258540) closed the transaction.

Latest news about SL Therapeutics, Inc.

StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	14/22/14	CI
StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	28/22/28	CI
StemLab Inc. announced that it has received KRW 4 billion in funding	04/21/04	CI
StemLab Inc. announced that it expects to receive KRW 4 billion in funding	24/21/24	CI
StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.	27/20/27	CI
StemLab Inc. announced that it expects to receive KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd. and another investor	21/19/21	CI
StemLab Inc. announced that it has received KRW 1.5 billion in funding	29/19/29	CI
StemLab Inc. announced that it expects to receive KRW 1.5 billion in funding	14/19/14	CI

SL Therapeutics Inc, formerly Stem Lab Inc, is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company is principally engaged in the development, research, manufacture and sale of biopharmaceuticals such as stem cell culture mediums, stem cell treatment as well as others.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
SL THERAPEUTICS, INC.	+23.94%	27.86L
CSL LIMITED	-1.62%	8.92TCr
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	4.05TCr
BIOGEN INC.	-15.59%	3.28TCr
UCB	+64.13%	2.62TCr
BIOMARIN PHARMACEUTICAL INC.	-21.54%	1.45TCr
INCYTE CORPORATION	-8.19%	1.31TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	1.16TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	1.15TCr
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	881.83Cr

Biopharmaceuticals

SL Therapeutics, Inc.

Equities

A258540

KR7258540004

Pharmaceuticals

StemLab Inc. announced that it has received KRW 1.5 billion in funding

Latest news about SL Therapeutics, Inc.

Chart SL Therapeutics, Inc.

Company Profile

Sector Biopharmaceuticals